Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioVaxys TechnologyFRA:5LB0 Days Payable is 0.00 as of Jul. 2025. Among 702 Biotechnology companies, BioVaxys Technology ranks worse than 142450% on this metric.
The historical rank and industry rank for BioVaxys Technology's Days Payable or its related term are showing as below:
FRA:5LB0's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 110.85 * Ranked among companies with meaningful Days Payable only.
BioVaxys Technology's Days Payable
stayed the same
from Jul. 2024 (0.00) to Jul. 2025 (0.00).
stayed the same
The historical data trend for BioVaxys Technology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5LB0 vs BPTH, AZTR, CLDI: Days Payable Comparison
For the Biotechnology subindustry, BioVaxys Technology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVaxys Technology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Days Payable distribution charts can be found below:
* The bar in red indicates where BioVaxys Technology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioVaxys Technology's Days Payable for the fiscal year that ended in Oct. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVaxys Technology (FRA:5LB0) has a Days Payable of 0.00 as of Jul. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioVaxys Technology and its competitors. According to the industry distribution chart, BioVaxys Technology ranks #999999 out of 702 companies in the Biotechnology industry.
Is BioVaxys Technology's Days Payable too high?
BioVaxys Technology's current Days Payable is 0.00. Based on the distribution chart, BioVaxys Technology ranks #999999 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does BioVaxys Technology's Days Payable compare to BPTH and AZTR?
According to the Biotechnology industry distribution chart, BioVaxys Technology ranks #999999 out of 702 companies for Days Payable. This places BioVaxys Technology in the lower half of its industry. The industry median Days Payable is 110.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.85, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioVaxys Technology and its competitors. For the Biotechnology industry, the median Days Payable is 110.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVaxys Technology's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVaxys Technology stock overvalued right now?
BioVaxys Technology (FRA:5LB0) has a current Days Payable of 0.00. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioVaxys Technology (FRA:5LB0), the current Days Payable is 0.00 as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5LB0 has been successfully added to your 
